Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Alan P Skarbnik, MD, Mary E Dilorenzo, APN, Michele Simone, APN, Scott D. Rowley, MD, David H. Vesole, MD PhD, Maribel Pereiras, Pharm D, Tracy Andrews, MSc, Andrew L. Pecora, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2018-99-113639

Published: 2018

Journal Articles

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Ricardo Parrondo, MD, Tracy Andrews, MSc, Rima M Panchal, MD, Sejal Kothadia, MD, Camille Johnson, MD, Jieqi Liu, Giselle Alexandra Suero-Abreu, MD PhD, David H. Vesole, MD PhD, David S Siegel, MD PhD, Noa Biran, MD

Blood (2018) 132 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2018-99-113722

Published: 2018

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phyllis McKiernan, David S Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MSc, Noa Biran, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Jacquelyn Callahan, RN, Andrea Ortega, RN, Mariefel Vendivil, RN, Supreet Kaur, MD, Marshall McKenna, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2018-99-117313

Published: 2018

Journal Articles

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

James K McCloskey, MD, Genique Stanislaus, ANP, Jamie L. Koprivnikar, MD, Tracy Andrews, PhD, Jones Elizabeth, Danielle Marcotulli, APN, Grace Perry, APN, Stuart L. Goldberg, MD, Stefan Faderl

Blood (2017) 130 (Supplement 1): 5050.

https://doi.org/10.1182/blood.V130.Suppl_1.5050.5050

Published: 2017

Journal Articles

Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience

Miguel Gonzalez Velez, MD, Tracy Andrews, PhD, Narjust Duma, MD, Ning Dong, MD, Badal Thakkar, MD MPH, Giselle Suero, MD PhD, Joshua R Richter, MD, David H. Vesole, MD PhD, David Siegel, MD PhD, Noa Biran, MD

Blood (2017) 130 (Supplement 1): 3062.

https://doi.org/10.1182/blood.V130.Suppl_1.3062.3062

Published: 2017

Journal Articles

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, David H. Vesole, MD PhD, Scott D. Rowley, MD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 2013.

https://doi.org/10.1182/blood.V130.Suppl_1.2013.2013

Published: 2017

Journal Articles

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Lori A. Leslie, MD, Sejal Kothadia, MD, Ewelina Protomastro, MS, Patricia J Greenberg, Tracy Andrews, PhD, Ann McNeill, ANP, Hoshiyuki Iida, Alan P Skarbnik, MD, Xiao Yang, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, Tatyana A Feldman, MD, Andre Goy, MD

Blood (2017) 130 (Supplement 1): 4163.

https://doi.org/10.1182/blood.V130.Suppl_1.4163.4163

Published: 2017

Journal Articles

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Nino Aleksidze, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4538.

https://doi.org/10.1182/blood.V130.Suppl_1.4538.4538

Published: 2017

Journal Articles

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Noa Biran, MD, Tracy Andrews, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Joshua Zenreich, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Robert Korngold, PhD, David Siegel, MD PhD

Blood (2017) 130 (Supplement 1): 1831.

https://doi.org/10.1182/blood.V130.Suppl_1.1831.1831

Published: 2017

Journal Articles

Antibiotic Overload: Antibiotic Stewardship in Febrile Patients with Hematologic Malignancies

Ricardo Parrondo, MD, Veronica Mariotti, MD, Camille Johnson, MD, Faiz Afridi, MD, Tracy Andrews, PhD, Lori A. Leslie, MD

Blood (2017) 130 (Supplement 1): 3402.

https://doi.org/10.1182/blood.V130.Suppl_1.3402.3402

Published: 2017

Journal Articles

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Rima M Panchal, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Nino Aleksidze, MD, Andrew L. Pecora, MD, Andre Goy, MD, Maribel Pereiras, Pharm D, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3283.

https://doi.org/10.1182/blood.V130.Suppl_1.3283.3283

Published: 2017

Journal Articles

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3284.

https://doi.org/10.1182/blood.V130.Suppl_1.3284.3284

Published: 2017

Journal Articles

5-Day Decitabine with Mini Fludarabine and Busulfan Yields Comparable Outcomes to Mini Flu/Bu but with Increased Incidence of Severe Acute GvHD

Melissa Baker, APN, Tracy Andrews, MA, Scott D. Rowley, MD, Andrew L. Pecora, MD, Alan P Skarbnik, MD, David H. Vesole, MD PhD, Andre Goy, MD, Maria Cortes, APN, Angelica Panganiban, RN, Michele L. Donato, MD

Blood (2016) 128 (22): 3422.

https://doi.org/10.1182/blood.V128.22.3422.3422

Published: 2016

Journal Articles

Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings

Phyllis McKiernan, APN, MSN, David S. Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MA, Scott D. Rowley, MD, Noa Biran, MD, Joshua R. Richter, MD, Andrew L. Pecora, MD, Alan P Skarbnik, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2016) 128 (22): 2302.

https://doi.org/10.1182/blood.V128.22.2302.2302

Published: 2016

Journal Articles

Features and Outcome of Patients (Pts) with New Diagnosis of Acute Myeloid Leukemia (AML) with Monocytic Differentiation (AML-Mo) Following Standard Induction Therapy. Do We Need a Different Strategy?

James K. McCloskey, MD, Samantha Depadova, Jamie L. Koprivnikar, MD, Tracy Andrews, MA, Marshall McKenna, BA, Genique Stanislaus, ANP, Stuart L. Goldberg, MD, Stefan Faderl, MD

Blood (2016) 128 (22): 4017.

https://doi.org/10.1182/blood.V128.22.4017.4017

Published: 2016

Journal Articles

Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters

Michele Boonstra, MSN APN, Melissa Baker, APN, Tracy Andrews, MA, Maria Cortes, APN, Ann Marie Maguire, BSN, Sarina Torres, BSN, Joshua Zenreich, BS, CCRP, Lina Starovoitova, BS, CCRP, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Andre Goy, MD, David H. Vesole, MD PhD, Michele L. Donato, MD

Blood (2016) 128 (22): 5735.

https://doi.org/10.1182/blood.V128.22.5735.5735

Published: 2016

Journal Articles

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation and Receive Salvage with Donor Lymphocyte Infusions (DLI)

Alan P Skarbnik, MD, Mary E DiLorenzo, APN, Tracy Andrews, MA, Phyllis McKiernan, APN, Scott D. Rowley, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana Feldman, MD, Lori A Leslie, MD, Lori A. Leslie, MD, Andrew L. Pecora, MD, Michele L. Donato, MD

Blood (2016) 128 (22): 5860.

https://doi.org/10.1182/blood.V128.22.5860.5860

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Largest Reported Series of Adults Who Received Treatment with Eculizumab (ECU) for Hematopoietic Cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). a Single Center Experience

Carfilzomib Cardiovascular Disease: Use of the Atherosclerotic Cardiovascular Disease Score to Predict Cardiovascular Events in Multiple Myeloma Patients Treated with Carfilzomib

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Antibiotic Overload: Antibiotic Stewardship in Febrile Patients with Hematologic Malignancies

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

5-Day Decitabine with Mini Fludarabine and Busulfan Yields Comparable Outcomes to Mini Flu/Bu but with Increased Incidence of Severe Acute GvHD

Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings

Features and Outcome of Patients (Pts) with New Diagnosis of Acute Myeloid Leukemia (AML) with Monocytic Differentiation (AML-Mo) Following Standard Induction Therapy. Do We Need a Different Strategy?

Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation and Receive Salvage with Donor Lymphocyte Infusions (DLI)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only